Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
InterMune second-quarter total revenue decreases to $5.9 million

InterMune second-quarter total revenue decreases to $5.9 million

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

PROVENGE receives FDA approval for treatment of CRPC

PROVENGE receives FDA approval for treatment of CRPC

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

UDH to participate in Abbott's new PLEX-ID BPEP

UDH to participate in Abbott's new PLEX-ID BPEP

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences doses first patient in Quad Phase III clinical program

ONGLYZA-metformin combination: FDA accepts NDA for review

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

FDA: Invirase-Norvir combination therapy for HIV may adversely affect the heart

FDA: Invirase-Norvir combination therapy for HIV may adversely affect the heart

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI